DGX vs. TEVA, VTRS, NBIX, BGNE, BMRN, AVTR, LH, RVTY, MEDP, and FMS
Should you be buying Quest Diagnostics stock or one of its competitors? The main competitors of Quest Diagnostics include Teva Pharmaceutical Industries (TEVA), Viatris (VTRS), Neurocrine Biosciences (NBIX), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), Avantor (AVTR), Laboratory Co. of America (LH), Revvity (RVTY), Medpace (MEDP), and Fresenius Medical Care (FMS). These companies are all part of the "medical" sector.
Teva Pharmaceutical Industries (NYSE:TEVA) and Quest Diagnostics (NYSE:DGX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, community ranking, dividends, analyst recommendations, profitability, earnings and valuation.
In the previous week, Quest Diagnostics had 63 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 66 mentions for Quest Diagnostics and 3 mentions for Teva Pharmaceutical Industries. Quest Diagnostics' average media sentiment score of 1.03 beat Teva Pharmaceutical Industries' score of 0.50 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.
Teva Pharmaceutical Industries received 787 more outperform votes than Quest Diagnostics when rated by MarketBeat users. Likewise, 67.53% of users gave Teva Pharmaceutical Industries an outperform vote while only 49.52% of users gave Quest Diagnostics an outperform vote.
Teva Pharmaceutical Industries has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Quest Diagnostics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.
Quest Diagnostics has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.
Teva Pharmaceutical Industries presently has a consensus price target of $13.78, suggesting a potential downside of 2.29%. Quest Diagnostics has a consensus price target of $146.17, suggesting a potential upside of 4.78%. Given Teva Pharmaceutical Industries' higher probable upside, analysts plainly believe Quest Diagnostics is more favorable than Teva Pharmaceutical Industries.
Quest Diagnostics has a net margin of 9.11% compared to Quest Diagnostics' net margin of -3.33%. Quest Diagnostics' return on equity of 34.90% beat Teva Pharmaceutical Industries' return on equity.
54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.8% of Quest Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Quest Diagnostics beats Teva Pharmaceutical Industries on 10 of the 18 factors compared between the two stocks.
Get Quest Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quest Diagnostics Competitors List
Related Companies and Tools
